Silexion Therapeutics
SLXN
7 hedge funds and large institutions have $258K invested in Silexion Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
75% more funds holding
Funds holding: 4 → 7 (+3)
0.94% more ownership
Funds ownership: 2.72% → 3.66% (+0.94%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$32.5K |
| 2 |
Moloney Securities Asset Management
Manchester,
Missouri
|
+$19.5K |
| 3 |
Virtu Financial
New York
|
+$13K |
| 4 |
StoneX Group
New York
|
+$9.8K |
Top Sellers
SLXN Hedge Fund Activity: Q2 2025 in Review
7 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q2 2025, worth a combined $258K — down 0.66% from $260K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLXN positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $32.5K.
- 7 institutional investors held Silexion Therapeutics (SLXN) as of Q2 2025, up from 4 in Q1 2025.
- Funds reported $258K of Silexion Therapeutics stock for Q2 2025, down 0.66% quarter-over-quarter.
- 3 funds opened new Silexion Therapeutics positions in Q2 2025 and 0 closed out, a net change of +3 holders.
- The largest Silexion Therapeutics buyer in Q2 2025 was UBS Group, an estimated $32.5K added.
Based on aggregated 13F filings for Q2 2025.